Maintenance Rituximab after High-Dose Therapy and Autologous Stem Cell Transplantation in Mantle Cell Lymphoma

Mantle cell lymphoma (MCL) is an aggressive B-cell lymphoma, which is characterized by early dissemination and an unfavorable clinical course. Treatment with conventional chemotherapy resulted in unsatisfactory outcomes and a median survival of less than 3 years after diagnosis of MCL [1]. During recent years, the prognosis of patients with MCL has improved considerably and the refinement of dose-intensified approaches such as autologous stem-cell transplantation (ASCT) has contributed significantly to this development.
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Source Type: research